Treatment of Maxillary Sinus Carcinoma: Clinical Results Using the Kitasato Modality
| Autor: | Kazuo Yao, Meijin Nakayama, Hiroomi Takahashi, Hiromi Nagai, Katsuhide Inagi, Makito Okamoto, Tomohiro Makoshi |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
Male medicine.medical_specialty Cellular immunity Maxillary sinus Maxillary Sinus Neoplasms medicine.medical_treatment Antineoplastic Agents Severity of Illness Index Hospitals University Picibanil Japan medicine.artery Outcome Assessment Health Care Carcinoma Deformity Humans Medicine Aged Neoplasm Staging Retrospective Studies Aged 80 and over business.industry Antineoplastic Protocols Radiotherapy Dosage General Medicine Middle Aged medicine.disease Superficial temporal artery Combined Modality Therapy Otorhinolaryngologic Surgical Procedures Surgery Survival Rate Radiation therapy Dissection medicine.anatomical_structure Otorhinolaryngology Maxilla Female Fluorouracil medicine.symptom business |
| Zdroj: | Acta Oto-Laryngologica. 122:15-19 |
| ISSN: | 1651-2251 0001-6489 |
| DOI: | 10.1080/000164802760057509 |
| Popis: | The conventional therapeutic regimen for maxillary sinus carcinoma consists of dissection of the maxilla, full-dose irradiation and extensive chemotherapy. However, the results obtained with this treatment are often poor. Even when patients recover, their quality of life is significantly reduced as a result of deformity of facial structures and swallowing and articulation dysfunctions. A retrospective analysis of 68 patients with maxillary sinus carcinoma treated with the Kitasato modality between 1975 and 1999 was conducted. All patients underwent pergingival maxillary sinus surgery combined with pre- and postoperative irradiation therapy with standardized total doses of 16 Gy; the postoperative irradiation was given in combination with regional intra-arterial infusion chemotherapy administered via the superficial temporal artery. All visible tumor lesions were removed where possible in order to preserve or facilitate cellular immunity after surgery. The cumulative 5-year survival rates were 85.7% for Stage II patients, 88.1% for Stage III, 76.6% for Stage IVA and 75.% for Stage IVB. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|